PHARMAXIS says today’s listing
of its Bronchitol (mannitol) on the
PBS is a significant breakthrough.
Developed in Australia and now
manufactured in Sydney, Bronchitol
is a spray-dried form of mannitol
which is delivered to the lungs by a
specially designed portable inhaler,
and the PBS listing is for the
treatment of cystic fibrosis in adults
and paediatric patients aged over
six years, either as add-on therapy
to domase alfa or in patients
intolerant of or inadequately
responsive to domase alfa.
About 3000 Australians suffer
from the genetic lung disease.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Aug 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Aug 12
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.